in vitro News and Research

RSS

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

LehmanMillet honored with four prestigious industry awards

HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.

9 Jan 2010

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

The Cystinosis Research Foundation of Irvine, Calif., announced it awarded $1.75 million in 11 new grants to researchers in the United States, Canada, Belgium and Italy who are working to find a cure for cystinosis, a rare, deadly metabolic and genetic disease that afflicts about 500 children and young adults in the U.S. and 2,000 worldwide.

7 Jan 2010

Prolias acquires UMBI's technology to develop human therapeutic antibodies

Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease, today announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI).

7 Jan 2010

Study suggests pomegranates may prevent growth of breast cancer cells

US scientists have carried out a series of laboratory tests suggesting that natural compounds in pomegranates may prevent the growth of breast cancer cells.

7 Jan 2010

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

The University of Maryland Biotechnology Institute (UMBI) today announced the exclusive licensing of a fully human antibody technology platform to Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease.

7 Jan 2010

Preclinical data of Geron's telomerase inhibitor drug published

Geron Corporation today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and inhibited the activity of glioblastoma stem cells in culture.

6 Jan 2010

BioPlex 2200 Anti-CCP test for early detection of RA launched

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield plc, an international in-vitro diagnostics (IVD) company, today announced the launch of Bio-Rad's BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis.

5 Jan 2010

Anti-aromatase phytochemicals in pomegranates reduce hormone-dependent breast cancer

Eating fruit, such as pomegranates, that contain anti-aromatase phytochemicals reduces the incidence of hormone-dependent breast cancer, according to results of a study published in the January issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

5 Jan 2010

ART publishes impressive data on its bioresorbable stent

Arterial Remodeling Technologies (“ART”) announced today that it has disclosed impressive in vivo and in vitro data related to its bioresorbable stent platform—data that validates the Company’s approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent without altering healing by drug elution from the stent platform.

5 Jan 2010

Cepheid granted EUA for Xpert Flu A Panel test

Cepheid today announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Xpert® Flu A Panel test.

4 Jan 2010

New chromosomal screening strategy shows promise in PGS

A new strategy that researchers believe provides a more comprehensive screening of the entire chromosomal makeup of an embryo shows tremendous promise in the field of preimplantation genetic screening (PGS) according to a study published in the December issue of Fertility and Sterility.

31 Dec 2009

Scientists develop straightforward technique to find ethnic origin of stem cells

An international team of scientists led by researchers at The Scripps Research Institute has developed a straightforward technique to determine the ethnic origin of stem cells.

30 Dec 2009

Nanoscaffolds could play a central role in tissue and organ reconstruction

Researchers from the University of Hong Kong and the Massachusetts Institute of Technology have published a study in the current issue of Cell Transplantation (18:9), now freely available on line at http://www.ingentaconnect.com/content/cog/ct, that explores ways to successfully keep stem cells "forever young" during implantation by slowing their growth, differentiation and proliferation.

28 Dec 2009

Brain circuit that holds the memory discovered

Ben W. Strowbridge, PhD, associate professor of neuroscience and physiology/biophysics, and Phillip Larimer, PhD, a MD/PhD student in the neurosciences graduate program at Case Western Reserve University School of Medicine, are the first to create stimulus-specific sustained activity patterns in brain circuits maintained in vitro.

28 Dec 2009

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

24 Dec 2009

CD20 deficiency in humans results in impaired T cell-independent antibody responses

Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis.

22 Dec 2009

BUSM researchers discover new gene therapy for treating emphysema patients

Researchers from Boston University School of Medicine (BUSM) have discovered a new gene therapy that may prevent the progression of emphysema. The study, which appears on-line in the Journal of Clinical Investigation, describes a method to express therapeutic genes in lung tissue for a lifetime after only a single treatment.

22 Dec 2009

TessArae's RM-Flu test granted FDA EUA

TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.

21 Dec 2009

Biovator and BASF sign collaboration agreement to develop In Vitro test systems

The Sweden-based biotech company Biovator and the global chemical industry leader BASF have signed a collaboration agreement for final development of In Vitro test systems capable of identifying the potential of chemical compounds to induce allergic reaction in humans. The agreement also includes a five-year BASF option of final product deliveries.

18 Dec 2009